Key Takeaways
- MV140 (Uromune) is a sublingual, non-antibiotic bacterial vaccine used in Europe and the UK to prevent recurrent urinary tract infections (UTIs).
- A 2022 randomized controlled trial in NEJM Evidence showed roughly 56–58% of women remained UTI-free after MV140 versus about 25% with placebo.
- Long-term UK follow-up (up to 9 years) and North American real-world data support durability and an excellent safety profile.
- MV140 is not FDA-approved in the United States as of April 2026.
- In endometriosis, urinary urgency, frequency, and bladder pain often reflect bladder endometriosis, pelvic inflammation, or neurofunctional dysfunction — not bacterial infection. An accurate diagnosis drives the right treatment.
Why This Topic Matters for Endometriosis Patients
For patients with recurrent urinary tract infections, the idea of a UTI vaccine can sound futuristic. In much of Europe, however, bacterial immunoprophylaxis for recurrent UTI is not a fringe concept. Agents such as OM-89 and, more recently, the sublingual polybacterial vaccine MV140 (marketed in several countries as Uromune) have been used as non-antibiotic prevention strategies in carefully selected patients. That matters because recurrent UTI is a major driver of repeated antibiotic exposure, microbiome disruption, and antimicrobial resistance.
At ESSI, we frequently see endometriosis patients who present with urinary urgency, frequency, pressure, or bladder discomfort that are not always caused by infection. In endometriosis, a hyperactive or irritated bladder can reflect bladder endometriosis, pelvic inflammation, adenomyosis-related mass effect, pelvic floor dysfunction, or neurogenic sensitization rather than recurrent bacterial cystitis. That distinction is critical. A patient with endometriosis-related bladder symptoms may need pelvic imaging, nerve-aware evaluation, or treatment of the underlying disease. A patient with culture-documented recurrent UTI may benefit from a prevention strategy such as immunoprophylaxis. Sometimes these two worlds overlap, but they are not the same problem.
This article brings together the strongest current evidence on MV140/Uromune — the pivotal randomized placebo-controlled trial, North American real-world data, long-term UK follow-up, a 2024 systematic review and meta-analysis, and current European Association of Urology (EAU) guidance — and explains how to think about UTI vaccines in the specific context of endometriosis.
What Is the MV140 (Uromune) UTI Vaccine?
The UTI vaccine drawing the most attention today is MV140, a sublingual preparation made from whole-cell, inactivated uropathogens. It includes four organisms commonly implicated in recurrent cystitis: Escherichia coli, Klebsiella pneumoniae, Enterococcus faecalis, and Proteus vulgaris. Rather than a classic single-antigen vaccine, MV140 is better understood as a mucosal bacterial immunotherapy. It is typically administered as a sublingual spray, two puffs under the tongue once a day for three months. The goal is not to treat an active infection, but to reduce future recurrences in patients with documented recurrent UTI.
Figure: MV140 (Uromune) is a sublingual preparation made from four inactivated uropathogens commonly responsible for recurrent cystitis.
How Does the MV140 UTI Vaccine Work?
The biologic rationale is attractive. By exposing the oral and sublingual mucosa to inactivated bacterial antigens, MV140 appears to stimulate both innate and adaptive immune responses. Published mechanistic work describes enhanced mucosal immune activation, antibody production, and broader trained-immunity effects that may improve the host response to common uropathogens. In practical terms, the vaccine is intended to make the urinary tract less vulnerable to repeated bacterial re-colonization while reducing dependence on continuous antibiotic prophylaxis.
What Do the Clinical Trials Show About MV140?
The most important efficacy study is the randomized, double-blind, placebo-controlled trial published in NEJM Evidence in 2022 by Lorenzo-Gómez, Foley, Nickel, and colleagues. Women with recurrent UTI were assigned to placebo, three months of MV140, or six months of MV140. The results were clinically meaningful: the median number of UTI episodes during follow-up was 3.0 in the placebo group versus 0.0 in both MV140 groups, and the proportion of women who remained UTI-free was about 25% with placebo versus roughly 56–58% with MV140. Notably, there was no clear signal that six months was better than three months, which supports the simpler three-month schedule.
Figure: Pivotal randomized placebo-controlled trial: % of women remaining UTI-free after 3 or 6 months of MV140 vs placebo (NEJM Evidence 2022).
What Does Real-World and Long-Term Evidence Show?
Real-world studies generally reinforce the trial signal, although they are observational and therefore less definitive. The first North American clinical experience — a Health Canada-approved, investigator-initiated Kingston, Ontario case series published by Nickel and colleagues in the Canadian Urological Association Journal in 2024 — reported a 75% reduction in UTI rate compared with the year before vaccination, with roughly 40% of women remaining UTI-free during the nine-month efficacy period. Secondary analyses from the randomized study also demonstrated fewer antibiotic prescriptions, lower symptom burden, and better quality-of-life outcomes after three months of MV140.
Long-term European experience is equally encouraging. The 2024 Journal of Urology meeting abstract from Kanabar, Foley, and Yang described up to nine years of follow-up in the UK Uromune cohort: 89 patients (72 women, 17 men) were evaluated, and approximately 54% remained UTI-free with an average infection-free duration of about 54.7 months. The safety record was excellent, with no adverse events reported during extended follow-up.
Figure: Real-world outcomes from the first North American MV140 study (Nickel 2024) and long-term UK Uromune follow-up (Kanabar 2024).
These numbers are impressive, but they should still be interpreted carefully because long-term observational follow-up is more hypothesis-generating than practice-defining. It tells us durability may be real; it does not replace the need for larger confirmatory randomized trials.
What Do the Guidelines Say About UTI Vaccines?
This is where nuance matters. The current European Association of Urology (EAU) guideline on urological infections acknowledges that immunomodulatory agents can reduce recurrent cystitis in the short term and specifically identifies OM-89 and MV140 as the most widely studied agents, with MV140 showing the most promising results. In a pooled analysis of placebo-controlled studies, patients receiving immunomodulation were roughly 50% more likely to remain cystitis-free in the short term. Even so, the recommendation is cautious because the overall evidence base remains limited, heterogeneous, and still in need of larger high-quality randomized trials. In other words, Europe is ahead of the United States in clinical adoption, but even Europe is not pretending the evidence is perfect.
Why This Matters for Endometriosis Patients
Endometriosis patients often describe urgency, frequency, pressure, burning, pain with bladder filling, or the sensation of a constant UTI even when urine cultures are negative. Urinary tract endometriosis — especially bladder endometriosis — can present with cyclic urgency, frequency, dysuria, and occasionally true recurrent UTI. Beyond direct bladder lesions, pelvic inflammation, pelvic floor guarding, central and peripheral sensitization, and overlap with bladder pain syndrome or overactive bladder can all mimic infection. That is why a negative culture in a symptomatic endometriosis patient should not automatically end the diagnostic workup, and a positive culture should not automatically explain every urinary symptom that patient has ever had.
Hyperactive Bladder in Endometriosis Is Not the Same as Recurrent UTI
This distinction is especially important for the patients we care for at ESSI. A hyperactive bladder in endometriosis often reflects a functional or inflammatory bladder problem rather than bacterial recurrence. Patients may have urgency and frequency because the bladder is being irritated by adjacent disease, because pelvic nerves have become sensitized, or because the pelvic floor is chronically overactive. Recurrent UTI, by contrast, is a microbiologic problem and should ideally be documented with culture when possible.
Figure: Recurrent UTI vs endometriosis-related bladder symptoms: two different problems, two different treatment plans.
Some endometriosis patients truly have both: chronic pelvic disease plus genuine recurrent infections. In those mixed cases, vaccine-based UTI prevention may reduce the infectious component, while excisional surgery for endometriosis, pelvic floor therapy, bladder-directed treatment, and neurofunctional strategies address the noninfectious component.
Where Could the MV140 UTI Vaccine Fit in Clinical Practice?
For the right patient, MV140 is appealing because it is non-antibiotic, biologically plausible, and increasingly supported by both trial data and real-world follow-up. The best candidates are patients with documented recurrent uncomplicated UTI who have exhausted simple preventive measures and want to avoid long-term antibiotic prophylaxis. It is not a substitute for diagnosing bladder endometriosis, urethral pathology, poor bladder emptying, stones, mesh complications, or neurogenic dysfunction. It is also not a treatment for culture-negative urgency and frequency mislabeled as infection. Used thoughtfully, however, it may become part of a precision strategy that spares antibiotics and improves quality of life.
Figure: A simplified decision framework: when MV140 may be appropriate vs when a targeted endometriosis workup is the right next step.
The ESSI Perspective on UTI Vaccines and Endometriosis
At ESSI, the message is simple: recurrent UTI and endometriosis-related bladder symptoms overlap, but they are not interchangeable. Patients deserve a workup that separates infection from inflammation, anatomy from neurobiology, and true bacterial recurrence from a chronic pelvic pain phenotype. UTI vaccines such as MV140/Uromune are one of the more interesting non-antibiotic developments in this space, and the European experience is real enough to deserve attention. The smartest use of this therapy, however, is in properly selected patients — not as a catch-all answer for every person with pelvic pressure and urinary urgency.
If you have endometriosis and persistent bladder symptoms, the right first step is a precise diagnosis by a team that understands both urologic and endometriosis care. Our approach at ESSI combines expert excision surgery with a careful evaluation of bladder and pelvic floor function, so that each patient receives the treatment that actually matches the underlying cause of their symptoms.
Bottom Line
MV140/Uromune is a promising non-antibiotic option for documented recurrent UTI, supported by a randomized controlled trial, observational North American data, long-term UK follow-up, and cautious endorsement in current European guidance. In endometriosis, however, urinary urgency and frequency often reflect bladder irritation, pelvic disease, or neurofunctional dysfunction rather than infection alone. Precision diagnosis — the hallmark of ESSI care — is what allows the right therapy, whether that is excisional endometriosis surgery, pelvic floor rehabilitation, bladder-directed treatment, or, in the right candidate, bacterial immunoprophylaxis.
Frequently Asked Questions
Is the MV140 UTI vaccine FDA-approved in the United States?
No. As of April 2026, MV140 (Uromune) is not FDA-approved in the United States. It is used in the UK and several European countries as a named-patient or unlicensed specialty product for recurrent UTI.
Can the UTI vaccine cure endometriosis-related bladder pain?
No. MV140 is designed to prevent bacterial UTI recurrence. It does not treat bladder endometriosis, pelvic floor dysfunction, or neurogenic bladder symptoms, which require a different diagnostic and treatment approach.
How is bladder endometriosis diagnosed?
Bladder endometriosis is usually identified with a detailed history, targeted pelvic examination, pelvic MRI, and — when indicated — cystoscopy. Definitive diagnosis requires surgical confirmation, typically at the time of excisional endometriosis surgery.
Who is a good candidate for the MV140 UTI vaccine?
Generally, adults with culture-documented recurrent uncomplicated UTI who have tried standard preventive measures and want to avoid continuous antibiotic prophylaxis. Candidacy should be assessed by a physician who can exclude non-infectious causes of urinary symptoms.
References
- Kanabar S, Foley SJ, Yang B. PD63-01. Evaluating the safety and effectiveness of Uromune® bacterial vaccine over a 9-year period in the UK: a study on managing recurrent urinary tract infection in men and women in the initial cohort. J Urol. 2024;211(5 Suppl):e1292. doi:10.1097/01.JU.0001009384.23104.ca.01. https://www.auajournals.org/doi/10.1097/01.JU.0001009384.23104.ca.01
- Lorenzo-Gómez MF, Foley S, Nickel JC, et al. Sublingual MV140 for prevention of recurrent urinary tract infections. NEJM Evid. 2022;1(4):EVIDoa2100018. doi:10.1056/EVIDoa2100018. https://evidence.nejm.org/doi/full/10.1056/EVIDoa2100018
- Nickel JC, Kelly K-L, Griffin A, Elterman S, Clark-Pereira J, Doiron RC. MV140 sublingual vaccine reduces recurrent urinary tract infection in women: results from the first North American clinical experience study. Can Urol Assoc J. 2024;18(2):25–31. doi:10.5489/cuaj.8455. https://pmc.ncbi.nlm.nih.gov/articles/PMC10841562/
- Nickel JC, Foley S, Yang B, et al. Reducing recurrent urinary tract infections in women with MV140 impacts personal burden of disease: secondary analyses of a randomized placebo-controlled efficacy study. Eur Urol Open Sci. 2024;63:96–103. doi:10.1016/j.euros.2024.03.010. https://pmc.ncbi.nlm.nih.gov/articles/PMC10995795/
- Mak Q, Greig J, Dasgupta P, Malde S, Raison N. Bacterial vaccines for the management of recurrent urinary tract infections: a systematic review and meta-analysis. Eur Urol Focus. 2024;10(5):761–769. doi:10.1016/j.euf.2024.04.002. https://pubmed.ncbi.nlm.nih.gov/38644097/
- European Association of Urology. EAU Guidelines on Urological Infections. EAU Guidelines Office; 2025. Available at: https://uroweb.org/guidelines/urological-infections
- Piriyev E, Schiermeier S, Römer T. Bladder endometriosis: diagnostic, therapy, and outcome of a single-center experience. Diagnostics (Basel). 2025;15(4):466. doi:10.3390/diagnostics15040466. https://pmc.ncbi.nlm.nih.gov/articles/PMC11854327/
- Li X, et al. Can bladder endometriosis be hard to diagnose? A two-case report and literature review. Front Med (Lausanne). 2025;12:1607689. doi:10.3389/fmed.2025.1607689. https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1607689/full
